Reported Earlier, Medtronic's PulseSelect PFA System Shows 98% Success in Treating Atrial Fibrillation, Study Reveals High Lesion Durability
Reported Earlier, Medtronic's PulseSelect PFA System Shows 98% Success in Treating Atrial Fibrillation, Study Reveals High Lesion Durability
早前報道，美敦力的PulseSelect PFA系統在治療心房顫動方面顯示出98%的成功率，研究顯示病變持久性高
Medtronic(MDT.US), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSelect Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). Invasive remapping conducted approximately two months post-ablation with the PulseSelect PFA System demonstrated durable isolation in 98% of pulmonary veins (PV) and 96% of patients had all veins isolated.
美敦力(MDt.US)作爲醫療科技領域的全球領導者，今天宣佈了臨床研究結果的發佈，展示了脈衝選擇脈衝場消融(PFA)系統治療房顫(Afib)時耐久性損傷形成的高比例。使用脈衝選擇PFA系統進行消融約兩個月後進行的侵入性重映射顯示，98%的肺靜脈（PV）實現了耐久性隔離，96%的患者所有靜脈被隔離。
Results were presented as a late breaking clinical trial at the Asia Pacific Heart Rhythm Society (APHRS) meeting in Sydney, Australia.
結果作爲一項遲發的臨床試驗在亞太心臟心律協會（APHRS）會議上在澳洲悉尼報告。
"Real-world evidence on chronic lesion formation and durability is critical as use...
"隨着PFA用於治療房顫的...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間